LONDON, June 5, 2014 /PRNewswire/ -- Elekta (NSE: EKTAb) and Royal Philips (NYSE: PHG, AEX: PHIA) announced today that The Institute of Cancer Research, London, a world-leading cancer research institution, working with its clinical partner The Royal Marsden NHS Foundation Trust, will join the Elekta MR Linac Research Consortium, a group with a mission to develop an integrated magnetic resonance imaging (MRI) guided radiation therapy system. Uniting an advanced digital linac with an MRI system would greatly enhance real-time visualization of cancer targets during the delivery of therapeutic radiation.
"The addition of The Institute of Cancer Research (ICR) to the consortium further strengthens this growing partnership of clinical centers," says Niklas Savander, Elekta President and CEO. "The ICR is a prominent cancer research institute and has contributed significantly in this arena for over a century. Its unique partnership with The Royal Marsden and 'bench-to-bedside' approach allows the ICR to deliver exceptional results. All of these factors make the ICR and The Royal Marsden a perfect fit as we advance MRI-guided radiotherapy."
"The development of MRI-guided radiation therapy establishes a new vision for clinical radiation oncology for the treatment of cancer," says Prof. Uwe Oelfke, MCCPM, FInstP, and Head of the Joint Department of Physics at The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust. "The translation of this novel technical approach into clinical practice faces a number of challenges ideally addressed by a group of world leading radiotherapy centers, each contributing with its specific expertise. Being a member of the consortium is a prerequisite to shape this exciting future of radiation therapy.
"Our current Cancer Research UK-funded research program on adaptive and image guided therapy," he continues, "together with the activities on MRI within our Cancer Research UK imaging center, are an excellent research environment to make leading contributions to the joint efforts of the consortium."
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV